Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent
Stopped Study did not accrue any participants, the PI has left the institution.
Conditions
- Malignant Ovarian Clear Cell Tumor
- Malignant Ovarian Serous Tumor
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
- Stage IIIA Fallopian Tube Cancer
- Stage IIIA Ovarian Cancer
- Stage IIIA Primary Peritoneal Cancer
- Stage IIIB Fallopian Tube Cancer
- Stage IIIB Ovarian Cancer
- Stage IIIB Primary Peritoneal Cancer
- Stage IIIC Fallopian Tube Cancer
- Stage IIIC Ovarian Cancer
- Stage IIIC Primary Peritoneal Cancer
- Stage IV Fallopian Tube Cancer
- Stage IV Ovarian Cancer
- Stage IV Primary Peritoneal Cancer
Interventions
- BIOLOGICAL: Aldesleukin
- BIOLOGICAL: HER2Bi-Armed Activated T Cells
- OTHER: Laboratory Biomarker Analysis
- BIOLOGICAL: Sargramostim
Sponsor
Barbara Ann Karmanos Cancer Institute
Collaborators